Skip to content

Study · Animal study (in vivo) · rat · 2020

9 results

Nicotinamide mononucleotide administration after sever hypoglycemia improves neuronal survival and cognitive function in rats.

Wang X, Hu X, Zhang L, Xu X, Sakurai T

Brain research bulletin5 May 2020Cited by 20 (Europe PMC)

PMID32380185 (opens in a new tab)DOI10.1016/j.brainresbull.2020.04.022 (opens in a new tab)PepBankPUB-32380185
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after severe hypoglycemia, NMN reduced neuronal death by 83 ± 3%.

    In plain wordsIn rats after severe hypoglycemia, NMN reduced neuronal death by 83 ± 3%.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseNeuronal death
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Measurements

    Neuronal death reduction
    83%
    after severe hypoglycemia

    Source sentences

    Summary
    The addition of NMN reduced neuron death by 83 ± 3% (P < 0.05) after severe hypoglycemia.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after severe hypoglycemia, the NMN group showed recovery of hippocampal long-term potentiation.

    In plain wordsIn rats, NMN treatment accompanied recovery of hippocampal long-term potentiation reduced by severe hypoglycemia.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseHippocampal long-term potentiation
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    The hippocampal LTP was significantly reduced by severe hypoglycemia but showed recovery in the NMN addition group.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, NMN attenuated spatial learning impairment induced by severe hypoglycemia.

    In plain wordsIn rats, NMN reduced spatial learning impairment after severe hypoglycemia.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseSpatial learning impairment
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    NMN treatment also attenuated the severe hypoglycemia-induced spatial learning and memory impairment.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, NMN attenuated memory impairment induced by severe hypoglycemia.

    In plain wordsIn rats, NMN reduced memory impairment after severe hypoglycemia.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseMemory impairment
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    NMN treatment also attenuated the severe hypoglycemia-induced spatial learning and memory impairment.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats after severe hypoglycemia, NMN decreased hippocampal ROS accumulation.

    In plain wordsIn rats after severe hypoglycemia, NMN reduced reactive oxygen species accumulation in the hippocampus.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseHippocampal ROS accumulation
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    Mechanically, we showed that NMN administration decreased ROS accumulation, suppressed PARP-1 activation, and restored levels of NAD+ and ATP in hippocampus.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats after severe hypoglycemia, NMN suppressed hippocampal PARP-1 activation.

    In plain wordsIn rats after severe hypoglycemia, NMN reduced PARP-1 activation in the hippocampus.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseHippocampal PARP-1 activation
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    Mechanically, we showed that NMN administration decreased ROS accumulation, suppressed PARP-1 activation, and restored levels of NAD+ and ATP in hippocampus.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats after severe hypoglycemia, NMN restored hippocampal NAD levels.

    In plain wordsIn rats after severe hypoglycemia, NMN restored NAD levels in the hippocampus.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseHippocampal NAD levels
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    Mechanically, we showed that NMN administration decreased ROS accumulation, suppressed PARP-1 activation, and restored levels of NAD+ and ATP in hippocampus.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats after severe hypoglycemia, NMN restored hippocampal ATP levels.

    In plain wordsIn rats after severe hypoglycemia, NMN restored ATP levels in the hippocampus.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseHippocampal ATP levels
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    500 mmg/kg · intraperitoneal · one weekAs given in this study (rat).

    Source sentences

    Summary
    Mechanically, we showed that NMN administration decreased ROS accumulation, suppressed PARP-1 activation, and restored levels of NAD+ and ATP in hippocampus.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 09AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Mechanism

    In rats after severe hypoglycemia, 3-acetylpyridine reversed the protective effects of NMN.

    In plain wordsIn rats after severe hypoglycemia, 3-acetylpyridine reversed NMN's protective effects.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableReversal of NMN protection by 3-AP
    Study

    ratn: not reported in source

    insulin-induced severe hypoglycemia
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    All these protective effects were reversed by 3-acetylpyridine (3-AP), which generates inactive NAD+.
    1 context sentence
    Summary · context
    We used a rat model of insulin-induced severe hypoglycemia and injected NMN (500 mmg/kg, i.p., one week) following 30 min of severe hypoglycemia, at the time of glucose administration.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.